Federal Law's Unclear Boundaries Over Consumer Products

Why It Matters

A new Congressional Research Service report on the Federal Food, Drug, and Cosmetic Act preemption lands at a moment when the boundaries between federal and state authority over consumer products are being tested from multiple directions: by states banning food additives, restricting abortion medication, and cracking down on unauthorized e-cigarettes.

It also falls at the same time as the resignation of FDA Commissioner Marty Makary, who stepped down Tuesday after privately stating his opposition to the FDA's approval of flavored vapes, according to the New York Times. The report, updated May 8, 2026, offers Congress a detailed map of where federal law under the FD&C Act ends and state power begins.

The stakes are enormous. The FDA oversees products valued at $4.1 trillion, accounting for roughly 21 cents of every dollar U.S. consumers spend. How much of that regulatory territory belongs exclusively to Washington, and how much remains open to state action, shapes everything from pharmaceutical liability lawsuits to whether California can ban an ingredient the FDA has deemed safe.

The U.S. Constitution's Supremacy Clause gives federal law the upper hand when it conflicts with state law. But the FD&C Act (first enacted in 1938 and amended dozens of times since) has never resolved that tension cleanly. Congress has written explicit preemption language into some parts of the law and stayed silent in others, leaving courts to fill the gaps.

The result is a patchwork. States have historically regulated food, drugs, and consumer products under their general police powers, and courts have been reluctant to strip that authority away without clear congressional direction. At the same time, manufacturers facing state tort claims (product liability suits, failure-to-warn allegations, and consumer protection lawsuits) have increasingly turned to federal preemption as a shield.

The CRS report synthesizes decades of Supreme Court and appellate case law to answer a deceptively simple question: when does FDA approval or regulation mean a state can no longer act?

The Big Picture

A Framework Built Incrementally

The FD&C Act had no express preemption provisions at all until 1976, when Congress enacted the Medical Device Amendments. That law added Section 521, which bars states from imposing requirements on medical devices that are "different from, or in addition to" federal requirements. Since then, Congress has added preemption clauses for food labeling, cosmetics labeling and packaging, and certain tobacco product standards, but notably, never for prescription drugs.

That silence on prescription drugs has generated the most litigation. With no express preemption clause, courts have had to determine through the implied preemption doctrine whether the FDA's elaborate drug approval process displaces state tort claims. The Supreme Court has weighed in repeatedly, and the results have been asymmetric: brand-name drug manufacturers can still face state failure-to-warn claims unless there is "clear evidence" the FDA would have rejected the proposed warning, while generic manufacturers are largely shielded because they are legally required to keep their labels identical to the brand-name drug.

State Food Regulations Preemption

For food, the 1990 Nutrition Labeling and Education Act established a clearer framework, barring states from imposing labeling requirements that are "not identical" to federal standards. Courts have interpreted this to mean that states cannot require additional disclosures beyond what the FDA mandates, but they can enforce requirements that mirror federal law, and they can challenge voluntary label claims that the FDA has not specifically authorized.

The report highlights a telling example: a court found that a bread crumb product's "100% Grated Parmesan Cheese" label could face a state misleading-labeling claim, because the federal standard of identity for grated cheese does not address whether manufacturers may voluntarily add the "100%" modifier. Federal law set the floor; it did not authorize the additional claim.

On food ingredients, the report points to a significant ruling: a state ban on a botanical ingredient that the FDA had placed on its "generally recognized as safe" (GRAS) list was found not preempted. The court's reasoning, that federal law permits the ingredient's use but does not require it to be sold everywhere, has direct implications for the current wave of state legislation targeting food additives.

The Tobacco Model

The 2009 Family Smoking Prevention and Tobacco Control Act offers perhaps the most deliberate example of Congress managing the federal-state boundary. Section 916 of that law is structured in three parts: a preservation clause broadly protecting state and local authority, a preemption clause covering product standards and premarket review, and a savings clause explicitly preserving state authority over sales, distribution, access, advertising, and use.

Courts have consistently read this structure to mean that manufacturing and product standards belong to the federal government, while sales regulation remains a state and local prerogative. That is why local ordinances banning flavored e-cigarette sales have survived preemption challenges in the Second, Eighth, and Ninth Circuits, even as the FDA retains exclusive authority over what goes into the products themselves.

Political Stakes

For the Administration

The Trump administration's simultaneous pursuit of federal deregulation and expanded state authority creates a tension the FD&C Act preemption framework makes visible.

On drug importation, the report notes that at least one federal court found the FD&C Act occupies the entire field of pharmaceutical importation, preempting a state law that would have allowed residents to import drugs from Canada. If the administration pursues federal importation programs under Section 804 of the FD&C Act, that pathway is legally available, but state-level workarounds may not be.

On medication abortion, the Fourth Circuit ruled in 2025 that West Virginia's abortion ban, as applied to Mifepristone, was not preempted by the FDA's authorization of the drug. The court's reasoning (that FDA's risk management program establishes minimum safety rules but does not create a right to access the drug everywhere it may be legally prescribed) preserves broad state authority to restrict abortion access even for FDA-approved medications. At the same time, the same court left intact a lower court ruling that West Virginia's telemedicine restrictions on mifepristone prescribing were preempted by the 2023 FDA risk management program, which had eliminated an in-person visit requirement.

On food and the "Make America Healthy Again" agenda, the report's discussion of state authority over GRAS ingredients is directly relevant. If states move to ban food additives that the FDA has approved or deemed safe, the preemption analysis suggests those bans may survive, at least under current doctrine.

For Congress

The report's closing section is addressed directly to Congress, and its message is pointed: the current patchwork of express preemption provisions, implied preemption doctrine, and savings clauses produces few bright-line results. Courts routinely undertake granular, case-by-case analyses that preserve at least some state requirements in almost every context.

If Congress wants cleaner lines (either to expand federal preemption and provide manufacturers with more certainty, or to explicitly preserve more state authority), it will need to legislate specifically. The report notes that the degree of specificity in any new preemption provision matters enormously, because courts read express preemption clauses narrowly and look closely at what federal law actually requires or permits before finding a conflict with state law.

For the Public

For consumers, the practical stakes are significant. The scope of the FD&C Act preemption determines whether injured patients can sue drug and device manufacturers in state court, whether states can require additional warnings on food products, and whether local governments can restrict the sale of products that federal regulators have authorized. Courts have generally preserved those avenues, but the doctrine is contested, and the outcomes are highly fact-specific.

The Bottom Line

The CRS report makes two things clear. First, FDA approval does not automatically immunize manufacturers from state law liability or shield products from state regulation, except in specific, well-defined circumstances. Second, where Congress has been silent, courts have consistently leaned toward preserving state authority, applying a presumption against preemption that reflects the states' long-standing role in protecting public health.

For a Congress navigating competing pressures (from industries seeking regulatory certainty to states asserting authority over food safety, drug access, and consumer protection), this report is a reminder that the current framework was built incrementally and inconsistently. Changing it will require deliberate choices about which level of government should have the last word, and for which products.

Access the Legis1 platform for comprehensive political news, data, and insights.